Mass spectrometry-based proteomics of cerebrospinal fluid in pediatric central nervous system malignancies: a systematic review with meta-analysis of individual patient data.

"expression correlate with lower progression rates gamma-enolase (increases) brain tumors known to increase in various tumors kallikrein-6 (increases) metastasizing/infiltration degrades extracellular matrix facilitating ease of infiltration adverse events amyloid-like protein 2 (decrease) plasminogen (decrease) histidine-rich glycoprotein (decrease) thromboemobolism amyloid-like protein 2 exert inhibitory effects on coagulations factors plasminogen and histidine-rich glycoprotein deficiencies are prothombotic due to hypofibrinolysis apolipoprotein e (increase) calsyntenin-1 (increase) glypican-1 (increase) disintegrin and metalloproteinase domain-containing protein 10 (increase) spectrin beta chain brain 2 (increase) prosaposin receptor gpr37 (increase) sodium/potassium-transporting atpase subunit alpha-3 (increase) triosephosphate isomerase (decrease) progesteron-induced blocking factor 1 (decrease) neurotoxicity--involved in pathogenesis of neurodegenerative diseases or neuromuscular dysfinction alzheimer: apolipoprotein e calsyntenin-1 glypican-1 disintegran metalloproteinase domain-containing protein 10 parkinsonism: ceruloplasmin sodium/potassium-transporting atpase subunit alpha-3 and prosaposin receptor gpr37 (juvenile parkinson) neuromuscular dysfunction: spectrin beta chain brain 2 sodium/potassium-transporting atpase subunit alpha-3 neuromodulin (increase) gamma-enolase (increase) prosaposin receptor gpr37 (increase) prostaglanding-h2 d-isomerase (increase) immunoglobulin superfamily member 8 (increase) kallikrein-6 (increase) neuroprotective properties (as measure of neurotoxicity) three studies deposited original mass spectrometry raw files in the pride repository (cns-all pxd017415 [ ]; and brain tumors pxd022512 [ ] and pxd018226 [ ])."

"Declarations Ethics approval and consent to participateNot applicable. Competing interestsThe authors declares that they have no competing interests. Competing interests The authors declares that they have no competing interests."

"Funding Open access funding provided by Copenhagen University. Christian Mirian, M.D, was funded by The Research Fund of Rigshospitalet, Copenhagen University Hospital, Grant Number: E-22093-09. This work is part of the Danish nation-wide research program Childhood Oncology Network Targeting Research, Organisation & Life expectancy (CONTROL) and supported by the Danish Cancer Society (R-257-A14720) and the Danish Childhood Cancer Foundation (2019-5934 and 2020-5769)."